{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:54:01Z","timestamp":1793904841745,"version":"4.8.0"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    ABT-492 demonstrated potent antibacterial activity against most quinolone-susceptible pathogens. The rank order of potency was ABT-492 &gt; trovafloxacin &gt; levofloxacin &gt; ciprofloxacin against quinolone-susceptible staphylococci, streptococci, and enterococci. ABT-492 had activity comparable to those of trovafloxacin, levofloxacin, and ciprofloxacin against seven species of quinolone-susceptible members of the family\n                    <jats:italic>Enterobacteriaceae<\/jats:italic>\n                    , although it was less active than the comparators against\n                    <jats:italic>Citrobacter freundii<\/jats:italic>\n                    and\n                    <jats:italic>Serratia marcescens.<\/jats:italic>\n                    The activity of ABT-492 was greater than those of the comparators against fastidious gram-negative species, including\n                    <jats:italic>Haemophilus influenzae<\/jats:italic>\n                    ,\n                    <jats:italic>Moraxella catarrhalis<\/jats:italic>\n                    ,\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    , and\n                    <jats:italic>Legionella<\/jats:italic>\n                    spp. and against\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    and\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    . ABT-492 was as active as trovafloxacin against\n                    <jats:italic>Chlamydia trachomatis<\/jats:italic>\n                    , indicating good intracellular penetration and antibacterial activity. In particular, ABT-492 was more active than trovafloxacin and levofloxacin against multidrug-resistant\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    , including strains resistant to penicillin and macrolides, and\n                    <jats:italic>H. influenzae<\/jats:italic>\n                    , including \u03b2-lactam-resistant strains. It retained greater in vitro activity than the comparators against\n                    <jats:italic>S. pneumoniae<\/jats:italic>\n                    and\n                    <jats:italic>H. influenzae<\/jats:italic>\n                    strains resistant to other quinolones due to amino acid alterations in the quinolone resistance-determining regions of the target topoisomerases. ABT-492 was a potent inhibitor of bacterial topoisomerases, and unlike the comparators, DNA gyrase and topoisomerase IV from either\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    or\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    were almost equally sensitive to ABT-492. The profile of ABT-492 suggested that it may be a useful agent for the treatment of community-acquired respiratory tract infections, as well as infections of the urinary tract, bloodstream, and skin and skin structure and nosocomial lung infections.\n                  <\/jats:p>","DOI":"10.1128\/aac.47.10.3260-3269.2003","type":"journal-article","created":{"date-parts":[[2003,9,23]],"date-time":"2003-09-23T18:25:36Z","timestamp":1064341536000},"page":"3260-3269","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":104,"title":["In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone"],"prefix":"10.1128","volume":"47","author":[{"given":"Angela M.","family":"Nilius","sequence":"first","affiliation":[{"name":"Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus L.","family":"Shen","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Hensey-Rudloff","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel S.","family":"Almer","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Beyer","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene J.","family":"Balli","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingna","family":"Cai","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00394-2"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00110-3"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2032"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.680-688.2002"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907223410403"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1071"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2884"},{"key":"e_1_3_2_9_2","first-page":"292","volume":"41","year":"1996","unstructured":"Doern, G. V., A. B. Brueggemann, G. Pierce, G. H. P. Holley, Jr., and A. M. Rauch. 1996. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 to 1995 and detection of \u03b2-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a 30-center national surveillance study. Antimicrob. Agents Chemother.41:292-297.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1721-1729.2001"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/mmbr.61.3.377-392.1997"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.1.24-27.1995"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1994.tb00458.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2160-2165.2000"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W"},{"key":"e_1_3_2_16_2","unstructured":"Gump D. W. 1996. Antimicrobial susceptibility testing for some atypical microorganisms: chlamydiae mycoplasmas Rickettsia and spirochetes p. 212-229. In V. Lorian (ed.) Antibiotics in laboratory medicine 4th ed. The Williams & Wilkins Co. Baltimore Md."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.8.593"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/320181"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1310"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.5.659"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/313868"},{"key":"e_1_3_2_22_2","first-page":"549","volume":"57","year":"1984","unstructured":"Johnson, S. E., G. C. Klein, G. P. Schmid, and J. C. Feeley. 1984. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents. Yale J. Biol. Med.57:549-553.","journal-title":"Yale J. Biol. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1086"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02703140"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.174.5.1596-1603.1992"},{"key":"e_1_3_2_26_2","unstructured":"National Committee for Clinical Laboratory Standards. 1992. Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M26-T. National Committee for Clinical Laboratory Standards Villanova Pa."},{"key":"e_1_3_2_27_2","unstructured":"National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_28_2","unstructured":"National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing; ninth informational supplement. Approved standard M100-S11. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.178.14.4060-4069.1996"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2810"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1574"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.1999.tb01400.x"},{"key":"e_1_3_2_33_2","first-page":"100","volume":"31","year":"1989","unstructured":"Segreti, J., H. A. Kessler, K. S. Kapell, and G. M. Trenholme. 1989. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis.Antimicrob. Agents Chemother.31:100-101.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.12.2778"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/313452"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(96)00183-6"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00043.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.22.2.186"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2505"},{"key":"e_1_3_2_40_2","unstructured":"Wexler H. M. and S. M. Finegold. 1991. Antibacterial susceptibility tests: anaerobic bacteria p. 1133-1137. In A. Balows W. J. Hausler Jr. K. L. Herrmann H. D. Isenberg and H. J. Shadomy (ed.) Manual of clinical microbiology 5th ed. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.25.13991"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.10.3260-3269.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.10.3260-3269.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:52:40Z","timestamp":1645447960000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.10.3260-3269.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1128\/AAC.47.10.3260-3269.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.10.3260-3269.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]},"assertion":[{"value":"2003-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}